EC Number | Application | Comment | Organism |
---|---|---|---|
2.5.1.47 | drug development | cysteine biosynthetic pathway is absent in humans but essential in microbial pathogens, suggesting that it provides potential targets for the development of novel antibacterial compounds | Mycobacterium tuberculosis |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.5.1.47 | additional information | rational structure-guided design of nanomolar thiazolidine inhibitors of Mycobacterium tuberculosis CysK1 O-acetyl serine sulfhydrylase, discovered using the crystal structure of a CysK1-peptide inhibitor complex as template, pharmacophore modeling and in vitro screening, overview. Chemical synthesis leads to improved thiazolidine inhibitors with an IC50 value of 19 nM for the best compound, a 150fold higher potency than the natural peptide inhibitor with IC50 of 0.0029 mM | Mycobacterium tuberculosis |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.5.1.47 | O-acetyl-L-serine + hydrogen sulfide | Mycobacterium tuberculosis | - |
L-cysteine + acetate | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.5.1.47 | Mycobacterium tuberculosis | P9WP55 | - |
- |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.5.1.47 | O-acetyl-L-serine + hydrogen sulfide | - |
Mycobacterium tuberculosis | L-cysteine + acetate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.5.1.47 | CysK1 | - |
Mycobacterium tuberculosis |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
2.5.1.47 | pyridoxal 5'-phosphate | dependent on | Mycobacterium tuberculosis |